These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24794596)

  • 1. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
    Davis TM
    Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
    Schernthaner G; Sattar N
    J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
    [No Abstract]   [Full Text] [Related]  

  • 3. New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
    Mitka M
    JAMA; 2013 Oct; 310(14):1435-6. PubMed ID: 24104360
    [No Abstract]   [Full Text] [Related]  

  • 4. New oral hypoglycaemics fail to show cardiovascular benefits.
    Cohen D
    BMJ; 2013 Sep; 347():f5458. PubMed ID: 24014343
    [No Abstract]   [Full Text] [Related]  

  • 5. An update on the 'gliptins'.
    Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 7. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 8. Saxagliptin and tuberculosis.
    Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
    [No Abstract]   [Full Text] [Related]  

  • 9. Saxagliptin, alogliptin, and cardiovascular outcomes.
    Standl E
    N Engl J Med; 2014 Jan; 370(5):483. PubMed ID: 24476445
    [No Abstract]   [Full Text] [Related]  

  • 10. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
    Jialal I; Dhindsa S
    Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
    [No Abstract]   [Full Text] [Related]  

  • 11. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
    Simó R; Hernández C
    Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
    [No Abstract]   [Full Text] [Related]  

  • 12. Saxagliptin (Onglyza) for type 2 diabetes.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):85-6. PubMed ID: 19890244
    [No Abstract]   [Full Text] [Related]  

  • 13. Diabetes: Cardiovascular safety of 'gliptin' therapy.
    Lim GB
    Nat Rev Cardiol; 2013 Nov; 10(11):616. PubMed ID: 24042219
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacotherapy: Cardiovascular safety of antihyperglycaemic drugs in patients with type 2 diabetes mellitus.
    Greenhill C
    Nat Rev Endocrinol; 2013 Nov; 9(11):625. PubMed ID: 24061081
    [No Abstract]   [Full Text] [Related]  

  • 15. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 16. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin, alogliptin benzoate, and ospemifene.
    Hussar DA; Frimpong JO
    J Am Pharm Assoc (2003); 2013; 53(4):442-7. PubMed ID: 23892821
    [No Abstract]   [Full Text] [Related]  

  • 18. Saxagliptin + metformin. Mostly disadvantages.
    Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
    [No Abstract]   [Full Text] [Related]  

  • 19. [The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
    Špinar J; Špinarová L; Vítovec J
    Vnitr Lek; 2015 Nov; 61(11):976-83. PubMed ID: 26652787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New antihyperglycemic drugs. Examination of cardiovascular outcomes with alogliptin versus standard of care (EXAMINE) and saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI 53)].
    Gallwitz B; Nitschmann S
    Internist (Berl); 2014 Jul; 55(7):859-62. PubMed ID: 24969610
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.